ICD-10 Coding for Elevated CA-125(R97.1, R97.1B, R97.1E)
Learn about the ICD-10 coding for elevated CA-125, including documentation requirements, coding pitfalls, and billing considerations.
Complete code families applicable to Elevated CA-125
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| R97.1 | Elevated cancer antigen 125 [CA 125] | Use when CA-125 is elevated without a confirmed malignancy diagnosis. |
|
| C56 | Malignant neoplasm of ovary | Use as primary code when ovarian cancer is confirmed. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutElevated CA-125
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Elevated CA-125.
Omitting clinical context for elevated CA-125
Impact
Clinical: May lead to misinterpretation of lab results., Regulatory: Increases risk of audit due to incomplete documentation., Financial: Potential for denied claims due to lack of supporting documentation.
Mitigation
Always include clinical context in documentation., Ensure lab results are accompanied by relevant clinical findings.
Using R97.1 as primary code for active ovarian cancer treatment
Impact
Reimbursement: Incorrect sequencing can lead to reduced reimbursement., Compliance: May trigger audits for incorrect coding., Data Quality: Affects accuracy of patient records and data reporting.
Mitigation
Sequence C56 as primary and R97.1 as secondary.
Incorrect sequencing of codes
Impact
Using R97.1 as primary code when malignancy is present.
Mitigation
Educate coders on proper sequencing rules and provide regular audits.